参考文献/References:
1. Harbet JC. Nuclear medicine thyrapy, Thieme Medical Publishers, InC. New York, 1987;37
2. Maisay MN. Clinical nuclear medicine. Chapman & Hall Medical, London 1991;P 222-234
3. Mazzaferri EL et al. Medicine, 1977;56:171
4. Black EG et al. Lancet, 1981;11:443-445
5. Brendel AJ et al. Eur J Nucl Med, 1990;16;35
6. 管昌田.中华核医学杂志, 1992;12:22-23
7. Bianchi R et al. J Nucl Med, 1993;34:2032-2037
8. Van Sorge-Van Boxtel RAJ et al. Nucl Med Com-mun, 1993;14;365-372
9. Barsano CP et al. Arch Intern Med, 1982, 142:763
10. Drape H et al. Acta Endocrinol, 1985;108;504
11. Rubello D et al. J Endocrinol Invest, 1990;13;737-742
12. Rubello D et al. J Nucl Med, 1992;33;1478-1480
13. pacini F et al. Acta Endocrinol, 1988;119;373-379
14. 管昌田.国外医学·放射医学核医学分册, 1987;11:164-168
15. Comtois R et al. J Nucl Med, 1993;34:1927-1930
16. Ramanna L et al. Clin Nucl Med, 1985;10; 687-689
17. pons F et al. Clin Nucl Med, 1987;12;644-647
18. Charkcs ND et al. J Nucl Med, 1990;31:147-153
19. Muller SP et al. J Nucl Med, 1990;31:407
20. Brendel AJ. J Nucl Med, 1988;29:1515-1520
21. Girelli ME et al. Eur J Nucl Med, 1985;10:252-254
22. Moser E et al. Nucl Med Commun, 1988;9:262-266
23. Elgazzar AH et al. Nucl Med Commun, 1993;14:96-103
24. Venuta S et al. J Nucl Med, 1979;23:163-166
25. Ling M et al. J Nucl Med, 1986;127:887
26. Hoefnagel CA et al. J Nucl Med, 1986;27:1854-1857
27. Iida Y et al. J Nucl Med, 1991;32:2098-2100
28. Caner B et al. J Nucl Med, 1992;33, 319-324
29. Cumali A et al. Clip Nucl Med, 1992;17:171
30. McEwan AJB et al. J Nucl Med, 1991;32:921
31. Salabe GB. J Nucl Med Alli Sci, 1990;34:304-308
32. Nagataki S.国外医学·放射医学核医学分册, 1989;13, 81-82
33. Fairweather DS et al. Clip Endocrinol, 1983;18:563
34. 管昌田.分化型甲状腺癌131I治疗方案(讨论稿). 第二届全国核素治疗研讨会论文汇编, 1993.
35. Mazzaferri EL et al. Am J Med, 1981;70:511
36. Andreol M et al. Advances in thyroid neoplasia. Rome, Field Education of Italia, 1981:341
相似文献/References:
[1]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[2]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[3]叶智轶,王辉,吴靖川.维甲酸在诱导再分化治疗分化型甲状腺癌中的价值[J].国际放射医学核医学杂志,2007,31(4):221.
YE Zhi-yi,WANG Hui,WU Jing-chuan.The value of retinoic acid-induced redifferentiation in the treatment of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(4):221.
[4]徐海青,吴边.131I合并小剂量碳酸锂治疗Graves病的临床探讨[J].国际放射医学核医学杂志,2006,30(3):151.
XU Hai-qing,WU Bian.Clinical investigation of 131I therapy combined with low-dose lithium carbonate for Graves disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(4):151.
[5]马寄晓,叶大铸.奥曲肽及其类似物用于肿瘤治疗的进展[J].国际放射医学核医学杂志,2005,29(2):79.
MA Ji-xiao,YE Da-zhu.Advances in tumor treatment with labeled somatostatin analogues[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(4):79.
[6]罗全勇,朱瑞森.分化型甲状腺癌患者血清Tg和TgAb检测与结果分析应注意的问题[J].国际放射医学核医学杂志,2004,28(5):197.
LUO Quan-yong,ZHU Rui-sen.Critical problems in the measurement and clinical evaluation of serum thyroglobulin and thyroglobulin antibody in differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):197.
[7]丁昊,叶斌,雷勇.增强DTC病灶摄取131I功能的措施[J].国际放射医学核医学杂志,2001,25(4):145.
DING Hao,YIE Bin,LEI Yong.The augmentation of 131I uptake of DTC[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(4):145.
[8]康玉国.分化型甲状腺癌18F-FDG PET显像的临床应用[J].国际放射医学核医学杂志,2000,24(6):264.
KANG Yuguo.Application of 18F-FDG PET scan in patients with differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(4):264.
[9]陈可靖.甲状腺癌131I显像假阳性的分析及鉴别诊断[J].国际放射医学核医学杂志,2000,24(1):11.
CHEN Ke-jing.The analysis and diferentiate diagnosis of false positive 131I imaging in metastatic thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(4):11.
[10]张渊琪,赵德善.分化型甲状腺癌的治疗进展[J].国际放射医学核医学杂志,2017,41(2):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]
Zhang Yuanqi,Zhao Deshan.Advances in the treatment of differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(4):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]